Pharmaceuticals
![](https://image.cnbcfm.com/api/v1/image/107378083-1708939558478-gettyimages-1586472684-DENMARK_NOVO.jpeg?v=1708939568)
Zealand Pharma soars 32% after promising weight-loss drug results
Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. ...
![](https://image.cnbcfm.com/api/v1/image/107364659-17062120752021-04-23t143717z_874125966_rc2q1n9nf728_rtrmadp_0_health-coronavirus-eu-pfizer.jpeg?v=1706212117&w=1920&h=1080)
Pfizer (PFE) Q4 earnings report 2023
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit ...
![](https://image.cnbcfm.com/api/v1/image/106974800-1636726117188-gettyimages-1234001052-RAFAPRESS_15072021-9655.jpeg?v=1705948573&w=1920&h=1080)
Johnson & Johnson (JNJ) earnings Q4 2023
The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Rafael Henrique | SOPA Images | ...
Forget the “Magnificent Seven” — This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher
You’ve no doubt heard a lot about the “Magnificent Seven” stocks. Each stock in this group — Apple, Microsoft, Alphabet, ...
![](https://image.cnbcfm.com/api/v1/image/107359960-1705462078513-gettyimages-1763768189-AFP_33ZV8LF.jpeg?v=1705462125&w=1920&h=1080)
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
The headquarters of US biopharmaceutical company Vertex Pharmaceuticals in Boston, Massachusets, on November 4, 2023. Joseph Prezioso | Afp | ...
![](https://image.cnbcfm.com/api/v1/image/107327102-1701804272247-107327102-16988587922023-10-30t154234z_1924471395_rc2234a6fa1u_rtrmadp_0_usa-labor-pharmacists.jpg?v=1705005458)
CVS to close ‘select’ pharmacies in Target stores in the coming months
CVS Health plans to close select pharmacies inside Target stores early this year, a company spokesperson said Thursday, as retail ...
![](https://stanforddaily.com/wp-content/uploads/2022/12/mtl2.png)
Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance
Marc Tessier-Lavigne told shareholders in 2009 that his research would “turn our current understanding of Alzheimer’s upside down.” Now, the ...